Trial Profile
NEOADJUVANT RADIOIMMUN THERAPY WITH CETUXIMAB IN PATIENTS WITH ADVANCED TUMORS OF THE HEAD NECK REGION( NEOADJUVANTE RADIOIMMUNTHERAPIE MIT CETUXIMAB IN PATIENTEN MIT FORTGESCHRITTENEN TUMOREN DER KOPF-HALSREGION)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
- 09 Sep 2018 Status changed from recruiting to completed.
- 27 Jun 2011 New trial record